Home > English articles > Treatment > Rheumatism, Bechterew disease, mast cells and palmitoylethanolamide

Rheumatism, Bechterew disease, mast cells and palmitoylethanolamide

Bechterew is a rheumatic disorder based on chronic inflammation. Since some years the treatment with the natural painkiller and anti-inflammation compound palmitoylethnanolamide in its new formulations containing micro-PEA gives new hope.

Rheumatoid and Bechterew pains are hard to treat. With the new natural bodily substance palmitoylethanolamide (PeaPure or een PEA-houdend product) we have a new effective pain relief at hand.

Both PeaPure and een PEA-houdend product contain a new optimal PEA formulation containing micro-PEA, to enhance the biological action of this natural compound in our body.

The substance has been tested on many thousands of patients with chronic pains and turned out to be an effective treatment in the studies each time.

It’s available as the supplement PeaPure in its most pure form without any chemical fillers (capsules 400 mg).

The bodily substance is a modulator of a number of cells that are involved in the trigger and maintenance of pain. One of those cells, the mast cell, is an example of a cell that produces all sorts of nasty pain-producing substances in the joints and joint capsules in case of rheumatism and Bechterew’s disease.

Here you can see one of those cells and all of the substances that the cell secretes. You don’t want too many of these in your joints! And exactly this cell, together with a number of other cells like the glia cells, plays an important part in pain and is calmed by palmitoylethanolamide.

Mast cells with rheumatism, Bechterew disease and palmitoylethanolamide

More and more, scientists are discovering new leads to solve the problems that play a role in rheumatism and rheumatoid related disease. For example, a lot more mast cells are found in the joints of patients with rheumatism than in the joints of healthy people. The worse the symptoms the more mast cells are present in the inflamed joint cap. From a series of experiments on animal models and other laboratory studies we now know that there is no joint inflammation without mast cells. This mast cell activity makes us understand why PeaPure is a good pain reliever to treat rheumatoid symptoms where mast cells are involved.

What do mast cells do?

Mast cells are an important part of the immune system. The name mast cells comes from the German word ‘Mast’ which means fattening, because they look plumb and filled with little grains. These grains contain all sorts of irritating substances, like histamine and so-called interleukins, which stimulate the immune system. This can be a good thing, but in case of rheumatism and related conditions this function escalates. Mast cells also play an important role in all sorts of allergies. Nobel prize winner professor Montalcini used to call them the prima donna cell of our immune system. Not only do mast cells accumulate in the joint caps, but also in the abnormalities and damages of the bone due to rheumatism, the so-called bone pannus and bone erosion. We also see mast cell concentrations in other forms of joint inflammation, like pediatric rheumatism, systemic lupus erythematous, psoriasis with arthritis, senior arthritis and osteoarthritis. These conditions also show an increased concentration of inflammation promoting substances secreted by the mast cells, like tryptase and histamine.  When mast cells go in to overdrive, like they do with certain infections, PeaCure can often bring the cells back to normal. Molecules called antibodies are attached to the outer layer of these cells. These antibodies fix themselves to foreign substances, like germs and allergen, and activate the mast cells again. The mast cells respond in turn by strongly activating the immune system and this creates an out-of-control inflammatory response. In case of rheumatism and for example Bechterew disease you’d rather not have these types of inflammations in your joints.

The negative inflammatory process in rheumatoid diseases

Antibodies are formed in our blood after we’ve in in contact with something that doesn’t belong in our body, like a virus or bacteria. Chronic conditions, like rheumatism, also create antibodies. The most common antibodies in rheumatism are called ACPA’s. We refer to these antibodies as rheumatoid factors and these were discovered as early as the 1950’s. These turn out to be autoantibodies. Autoantibodies are antibodies that target the body itself (auto means ‘self’).  These are frequently found in the blood even before rheumatism has been clinically diagnosed and often predict a serious progress of the disease. They also seem to play a role in the origin of inflammation. With rheumatism, the immune cells produce a lot of inflammatory proteins, part of those are called cytokines. There are different kinds of cytokines and they all give off signals, like messenger molecules. They’re important in the communication between cells, turn on the immune response or ensure that other cytokines are being produced. The cytokine called Interleukin-1 (IL-1) cause a fever response in case of inflammation. This helps to fight the infection, but in case of rheumatism too much of this IL-1 is produced. IL-1 is produced by the mast cells for example. Because of this the joints get painful, thick and stiff. Naturally, the bone and cartilage get damaged.

Prevention of joint conditions with medication

The consequences of joint inflammation due to rheumatism can be disastrous for the daily life and career of the patient. A lot of the misery can be avoided by starting to use powerful medicine in an early stage of the disease. Adrenal gland hormones (usually in the form of prednisone) are often used in the treatment of rheumatoid arthritis. Long-term use of these strong and general anti-inflammatories often cause serious side effects like weight gain, high blood pressure and diabetes. Therefore new treatments are necessary. These new treatments are now available, but unfortunately also come with a down side. The major disadvantage of the new generation rheumatoid inhibitors, the so-called biologicals or TNF inhibitors, is that they not only inhibit inflammation in the joints, but also the own defense against bacteria. Patients using a biological therefore run a higher risk of infectious disease.

Inhibit the overactive mast cells with palmitoylethanolamide

PEA is a body’s own anti-inflammatory and pain reliever. The substance is similar to the cannabis molecule, which is also a pain reliever. The advantage is that PEA doesn’t influence your perception and doesn’t make you stoned. It’s a useful dietary supplement that was identified in the 40’s by researchers from the Czech Republic. These discovered that adding egg yolks to the diet of underfed children decreased the frequency of infections. Further research showed that it was the substance palmitoylethanolamide, which is present in egg yolk, that was responsible for this effect. This became extra clear in a series of studies on hundreds of adults and children in the 70’s. Adding palmitoylethanolamide to their diet turned out to decrease the severity of flu symptoms and acute inflammation. PEA has been studied with a whole range of pain problems and always turned out to be safe and effective. There has been no major research of PEA for rheumatism and Bechterew disease, however the pain relieving properties alone and the potential to inhibit the inflammation caused by the mast cells justify the use of the substance. It has also been proven that chronic pain is often caused by chronic inflammation and with this substance you will kill 2 birds with one stone. As the substance has nearly no side effects it can easily be used with other rheumatoid medicine.


Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB: Mast cells: a cellular link between autoantibodies and inflammatoryarthritis. Science 2002, 297:1689-1692.

Corr M, Crain B: The role of Fcγ γR signaling in the K/B x N serum transfer model of arthritis. J Immunol 2002, 169:6604-6669. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997, 77:1033-1079.